No Benefit with Erbitux in KRAS Mutated Tumors

Patients whose colorectal cancer tumors had a mutation in the KRAS gene had no benefit from treatment with Erbitux® (cetuximab).  They lived no longer after Erbitux treatment began than patients who had no Erbitux.

Read Full Post

Changes in Blood Magnesium Levels Predict Response to Erbitux

Hypomagnesemia, or reduced magnesium levels, is a side effect of Erbitux® (cetuximab) treatment.  Patients with colorectal cancer whose blood magnesium dropped the fastest also had the best response to Erbitux given with Camptosar® (irinotecan) . Italian researchers measured magnesium levels for 68 patients before treatment…

Read Full Post
Page 2 of 212